A Study of LY3526318 in Healthy Women
Summary
The main purpose of this study is to learn more about how LY3526318 affects blood flow to the skin in healthy women. For each participant, the study will last up to 28 days and Part B will last up to 78 days, including screening and follow-up.
Timeline
- Start
- 2019-12-12
- Primary completion
- 2020-02-28
- Completion
- 2020-03-06
Outcome
Met primary endpoint
registry analysis (superiority test); Placebo vs 100 mg LY3526318; p = 0.02; Mean Difference (Final Values) -214.89 (90% CI -367.31 to -62.48); ANOVA NCT04183283 ↗
registry analysis (superiority test); Placebo vs 30 mg LY3526318; p <.0001; Mean Difference (Final Values) -191.02 (90% CI -268.37 to -113.67); ANOVA NCT04183283 ↗
registry analysis (superiority test); Placebo vs 100 mg LY3526318; p <.0001; Mean Difference (Final Values) -252.24 (90% CI -329.79 to -174.68); ANOVA NCT04183283 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3526318 | Unknown | 10 mg | Oral |
| Subject | LY3526318 | Unknown | 30 mg | Oral |
| Subject | LY3526318 | Unknown | 100 mg | Oral |
Indications
No indication recorded.